Annotation Detail
Information
- Associated Genes
- BTK
- Associated Variants
-
BTK MUTATION
BTK MUTATION - Associated Disease
- Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
- Source Database
- DisGeNET
- Description
- At the time of relapse, agents directed at activated pathways in MCL cells such as bortezomib (NFkB inhibitor), lenalidamide (anti-angiogenesis) and Ibruitinib (Bruton's Tyrosine Kinase [BTK] inhibitor) have demonstrated excellent clinical activity in MCL patients.
- Pubmed
- 26103436
- Section of the abstract supporting the evidence
- RISK-ADAPTED THERAPY
- Number of the section of the abstract supporting the evidence
- 4
- Number of the sentence supporting the evidence
- 15
- Original source reporting the Gene Disease association
- BeFree
- DisGENET score for the Gene Disease association
- 0.00190009310456212
Drugs